A clinical and radiological trial of meglumine loglycamate, a new intravenous cholangiographic contrast medium.
The efficacy of meglumine ioglycamate was assessed in 100 unselected patients who underwent cholangiography for various reasons. Good to excellent opacification was achieved in 69% of all patients. A total of 17% of all patients showed side-effects, the majority of which were transient and of a minor nature. Blood pressure and liver function were apparently not affected, but SGOT levels increased transiently within 24 hours in 21% of patients. Renal excretion of the contrast medium occurred in 48% of patients, but in only 2 did it interfere with visualisation of the duct.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002758:Cholangiography; D002765:Cholecystography; D003135:Common Bile Duct / Q000000981:diagnostic imaging; D005260:Female; D006801:Humans; D007463:Iodobenzoates; D007471:Ioglycamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000378:metabolism; D007668:Kidney / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D007463:Iodobenzoates; D007471:Ioglycamic Acid